Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

calcitonin salmon

×

Overview

What is Miacalcin?

Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish.

Miacalcin (calcitonin-salmon) Injection, Synthetic is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin. This is shown by the following graphic formula:

It is provided in sterile solution for subcutaneous or intramuscular injection. Each milliliter contains: calcitonin-salmon 200 International Units.

Inactive Ingredients (per mL):

The activity of Miacalcin injection is stated in International Units based on bioassay in comparison with the International Reference Preparation of calcitonin-salmon for Bioassay, distributed by the National Institute for Biological Standards and Control, Holly Hill, London.



What does Miacalcin look like?



What are the available doses of Miacalcin?

Miacalcin injection is available as a clear, colorless, sterile solution of synthetic calcitonin-salmon in individual 2 mL multi-dose vials containing 200 International Units per mL.

What should I talk to my health care provider before I take Miacalcin?

There are no data to support use in children ()

How should I use Miacalcin?

Miacalcin injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. There is no evidence that the prophylactic use of calcitonin-salmon is beneficial in asymptomatic patients. Miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).

The recommended dose of Miacalcin injection for treatment of symptomatic Paget’s disease of bone is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly.


What interacts with Miacalcin?

Sorry No Records found


What are the warnings of Miacalcin?

Sorry No Records found


What are the precautions of Miacalcin?

Sorry No Records found


What are the side effects of Miacalcin?

Sorry No records found


What should I look out for while using Miacalcin?

Hypersensitivity to calcitonin-salmon or any of the excipients. Reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat .


What might happen if I take too much Miacalcin?

The pharmacologic actions of Miacalcin injection suggest that hypocalcemic tetany could occur in overdose. Therefore, provisions for parenteral administration of calcium should be available for the treatment of overdose.

A dose of calcitonin-salmon l000 International Units subcutaneously may produce nausea and vomiting. Doses of 32 International Units per kg per day for 1 to 2 days demonstrate no other adverse effects. Data on chronic high-dose administration are insufficient to assess toxicity.


How should I store and handle Miacalcin?

Store at How SuppliedMiacalcin (calcitonin-salmon) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL.NDC 67457-675-02carton containing 1 x 2 mL multi-dose vialStorage and HandlingStore in refrigerator between 2° to 8°C (36° to 46°F).How SuppliedMiacalcin (calcitonin-salmon) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL.NDC 67457-675-02carton containing 1 x 2 mL multi-dose vialStorage and HandlingStore in refrigerator between 2° to 8°C (36° to 46°F).How SuppliedMiacalcin (calcitonin-salmon) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL.NDC 67457-675-02carton containing 1 x 2 mL multi-dose vialStorage and HandlingStore in refrigerator between 2° to 8°C (36° to 46°F).How SuppliedMiacalcin (calcitonin-salmon) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL.NDC 67457-675-02carton containing 1 x 2 mL multi-dose vialStorage and HandlingStore in refrigerator between 2° to 8°C (36° to 46°F).How SuppliedMiacalcin (calcitonin-salmon) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL.NDC 67457-675-02carton containing 1 x 2 mL multi-dose vialStorage and HandlingStore in refrigerator between 2° to 8°C (36° to 46°F).


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Calcitonin-salmon is a calcitonin receptor agonist. Calcitonin-salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action.

The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.

Non-Clinical Toxicology
Hypersensitivity to calcitonin-salmon or any of the excipients. Reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat .

MAO inhibitors should be used with caution in patients receiving hydrALAZINE

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydrALAZINE, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydrALAZINE are used concomitantly.





Administration of hydrALAZINE with food results in higher plasma levels.

Serious hypersensitivity reactions have been reported in patients receiving Miacalcin injection, e.g., bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis. Appropriate medical support and monitoring measures should be readily available when Miacalcin injection is administered. If anaphylaxis or other severe hypersensitivity/allergic reactions occur, initiate appropriate treatment .

For patients with suspected hypersensitivity to calcitonin-salmon, skin testing should be considered prior to treatment utilizing a dilute, sterile solution of Miacalcin injection. Healthcare providers may wish to refer patients who require skin testing to an allergist. A detailed skin testing protocol is available from the Mylan Pharmaceuticals Inc. Product Safety Department.

The following serious adverse reactions are discussed in greater detail in other sections of the label:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).